diclofenac has been researched along with Eye Disorders in 21 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diclofenac therapy was well tolerated, except in one patient, and may safely be used to reduce intraocular inflammation." | 6.66 | Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery. ( Berson, D; Ronen, S; Rozenman, Y; Zylbermann, R, 1985) |
| "An attempt has been made in the present study to formulate soluble ocular inserts of aceclofenac to facilitate the bioavailability of the drug into the eye, as no eye drop solution could be formulated." | 5.37 | Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation. ( Gilhotra, RM; Mathurm, M, 2011) |
| "Dexamethasone and diclofenac were equally effective in reducing postoperative inflammation after phacoemulsification and IOL implantation in eyes with no other disease than cataract." | 5.10 | Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. ( Laurell, CG; Zetterström, C, 2002) |
| "Forty healthy volunteers instilled Dicloabak in the randomised eye and thiomersal-preserved diclofenac in the other eye, according to a strictly identical dosing regimen, for 28 days." | 2.71 | [Ocular tolerance of a new formulation of nonpreserved diclofenac]. ( Chiambaretta, F; Creuzot-Garcher, C; Dubray, C; Pilon, F; Pouliquen, P; Rebika, H; Rigal, D, 2004) |
| "Thus diclofenac sodium was as effective an anti-inflammatory agent for postoperative inflammation as prednisolone acetate." | 2.67 | A comparison of topical non-steroidal anti-inflammatory drugs to steroids for control of post cataract inflammation. ( Brennan, KM; Brown, RM; Roberts, CW, 1993) |
| "Diclofenac therapy was well tolerated, except in one patient, and may safely be used to reduce intraocular inflammation." | 2.66 | Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery. ( Berson, D; Ronen, S; Rozenman, Y; Zylbermann, R, 1985) |
| " In vivo pharmacokinetics studies showed enhanced pre-corneal retention and penetration of the DIC/MPEG-PCL-CS nanosuspension, which resulted in a higher concentration of DIC (Cmax) in the aqueous humor and better bioavailability compared with commercial DIC eye drops (P < 0." | 1.42 | Chitosan grafted methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. ( Chen, H; Li, X; Liang, R; Luo, Z; Shi, S; Yu, J; Zhang, Z, 2015) |
| " Results of HET-CAM and ICE tests suggest that sulphacetamide is moderately toxic in the presence of light/UV-A and very slightly irritant without irradiation." | 1.40 | Photochemical toxicity of drugs intended for ocular use. ( Kaithwas, G; Kishor, K; Sahu, RK; Saraf, SA; Singh, B, 2014) |
| " These results suggest a great potential of our micelle formulations as a novel ocular drug delivery system to improve the bioavailability of the drugs." | 1.38 | Diclofenac/biodegradable polymer micelles for ocular applications. ( Chen, H; Li, J; Li, X; Sun, S; Weng, Y; Zhang, Z, 2012) |
| "An attempt has been made in the present study to formulate soluble ocular inserts of aceclofenac to facilitate the bioavailability of the drug into the eye, as no eye drop solution could be formulated." | 1.37 | Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation. ( Gilhotra, RM; Mathurm, M, 2011) |
| "Diclofenac was selected as the reference compound." | 1.31 | Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. ( Brady, MT; Gamache, DA; Graff, G; Spellman, JM; Yanni, JM, 2000) |
| "Inflammation was evaluated by clinical observations, biochemical analysis of aqueous humour and by histology." | 1.31 | Beneficial effects of topical anti-inflammatory drugs against sulfur mustard-induced ocular lesions in rabbits. ( Amir, A; Chapman, S; Fishbeine, E; Frishman, G; Gilat, E; Kadar, T; Liani, H; Meshulam, J; Sahar, R; Turetz, J, 2000) |
| " The authors did not observe any side-effects of the preparation, even after long-term administration or after short-term administration to neonates." | 1.31 | [Diclof 0.1% eyedrops in pediatric ophthalmology]. ( Gerinec, A; Kostolná, B, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katara, R | 2 |
| Sachdeva, S | 2 |
| Majumdar, DK | 2 |
| Zhu, Q | 1 |
| Liu, C | 1 |
| Sun, Z | 1 |
| Zhang, X | 1 |
| Liang, N | 1 |
| Mao, S | 1 |
| Sahu, RK | 1 |
| Singh, B | 1 |
| Saraf, SA | 1 |
| Kaithwas, G | 1 |
| Kishor, K | 1 |
| Shi, S | 1 |
| Zhang, Z | 2 |
| Luo, Z | 1 |
| Yu, J | 1 |
| Liang, R | 1 |
| Li, X | 2 |
| Chen, H | 2 |
| Mathurm, M | 1 |
| Gilhotra, RM | 1 |
| Li, J | 1 |
| Sun, S | 1 |
| Weng, Y | 1 |
| Laurell, CG | 1 |
| Zetterström, C | 1 |
| Aragona, P | 1 |
| Stilo, A | 1 |
| Ferreri, F | 1 |
| Mobrici, M | 1 |
| Chiambaretta, F | 1 |
| Creuzot-Garcher, C | 1 |
| Pilon, F | 1 |
| Pouliquen, P | 1 |
| Rebika, H | 1 |
| Dubray, C | 1 |
| Rigal, D | 1 |
| Kim, JS | 1 |
| Hwang, JM | 1 |
| Reim, M | 1 |
| von Kiether, R | 1 |
| Oglodek, C | 1 |
| Schaffelt, F | 1 |
| Thüne, G | 1 |
| Agata, M | 1 |
| Abe, T | 1 |
| Kon, M | 1 |
| Tanaka, M | 1 |
| Kimura, T | 1 |
| Nakajima, A | 1 |
| Herbort, CP | 1 |
| Mermoud, A | 1 |
| Schnyder, C | 1 |
| Pittet, N | 1 |
| Brennan, KM | 1 |
| Brown, RM | 1 |
| Roberts, CW | 1 |
| Koay, P | 1 |
| Gamache, DA | 1 |
| Graff, G | 2 |
| Brady, MT | 1 |
| Spellman, JM | 2 |
| Yanni, JM | 2 |
| Ke, TL | 1 |
| Amir, A | 1 |
| Turetz, J | 1 |
| Chapman, S | 1 |
| Fishbeine, E | 1 |
| Meshulam, J | 1 |
| Sahar, R | 1 |
| Liani, H | 1 |
| Gilat, E | 1 |
| Frishman, G | 1 |
| Kadar, T | 1 |
| Gerinec, A | 1 |
| Kostolná, B | 1 |
| Ronen, S | 1 |
| Rozenman, Y | 1 |
| Zylbermann, R | 1 |
| Berson, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study[NCT01995890] | Phase 4 | 327 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for diclofenac and Eye Disorders
| Article | Year |
|---|---|
The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Conjunctivitis, | 1996 |
6 trials available for diclofenac and Eye Disorders
| Article | Year |
|---|---|
Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery.
Topics: Aged; Aged, 80 and over; Cataract Extraction; Dexamethasone; Diclofenac; Double-Blind Method; Eye Di | 2002 |
Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cornea; Diclofenac; Dry Eye Syndromes; Epithel | 2005 |
[Ocular tolerance of a new formulation of nonpreserved diclofenac].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Schedule; Dry Eye Sy | 2004 |
Anti-inflammatory effect of diclofenac drops after argon laser trabeculoplasty.
Topics: Aged; Anterior Eye Segment; Diclofenac; Double-Blind Method; Drug Administration Schedule; Endophtha | 1993 |
A comparison of topical non-steroidal anti-inflammatory drugs to steroids for control of post cataract inflammation.
Topics: Cataract Extraction; Diclofenac; Eye Diseases; Humans; Inflammation; Lenses, Intraocular; Postoperat | 1993 |
Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery.
Topics: Aged; Cataract Extraction; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Eye Diseases; | 1985 |
14 other studies available for diclofenac and Eye Disorders
| Article | Year |
|---|---|
Enhancement of ocular efficacy of aceclofenac using biodegradable PLGA nanoparticles: formulation and characterization.
Topics: Administration, Ophthalmic; Animals; Arachidonic Acid; Calorimetry, Differential Scanning; Chemistry | 2017 |
Inner layer-embedded contact lenses for pH-triggered controlled ocular drug delivery.
Topics: Administration, Ophthalmic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cellulose; Contact Len | 2018 |
Design, characterization, and evaluation of aceclofenac-loaded Eudragit RS 100 nanoparticulate system for ocular delivery.
Topics: Acrylic Resins; Administration, Ophthalmic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell M | 2019 |
Photochemical toxicity of drugs intended for ocular use.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Chickens; Diclofenac; Eye Diseases; Humans; Irrit | 2014 |
Chitosan grafted methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac.
Topics: Animals; Chitosan; Diclofenac; Drug Carriers; Eye Diseases; Humans; Male; Mice; Ophthalmic Solutions | 2015 |
Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Chemistry, Pharmaceutical | 2011 |
Diclofenac/biodegradable polymer micelles for ocular applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aqueous Humor; Diclofenac; Drug Carriers; Eye Dise | 2012 |
Topical diclofenac for the treatment of eyeache in Miller-Fisher syndrome.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Eye Diseases; H | 2006 |
[Effect of inhibitors of prostaglandin synthesis on the eye].
Topics: Animals; Burns, Chemical; Diclofenac; Eye; Eye Burns; Eye Diseases; Humans; Indomethacin; Inflammati | 1983 |
[Effect of topical diclofenac sodium, a non-steroidal anti-inflammatory drug, on various ocular inflammatory models in animals].
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Aqueous Humor; Diclofenac; Eye Diseases; | 1983 |
Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2000 |
Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Biotransformation; Cornea; Dicl | 2000 |
Beneficial effects of topical anti-inflammatory drugs against sulfur mustard-induced ocular lesions in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cornea; Dermatologic Age | 2000 |
[Diclof 0.1% eyedrops in pediatric ophthalmology].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Diclofenac; Eye Diseas | 2001 |